Founded in science.
Focused on people.

Restoring the regenerative capacity of the brain and spinal cord.

A meticulous approach to translate new discoveries into unprecedented results

Novoron is pioneering drug development targeting low-density lipoprotein receptors, canonically mischaracterized as merely scavenger proteins. Our unique technology enables precise targeting at both whole-receptor and micro-domain levels. These breakthroughs offer new hope for treating a variety of diseases including our areas of focus, namely neurological damage and disease in the CNS (i.e. tauopathies - including Alzheimer's disease - multiple sclerosis, spinal cord injuries).

First-in-class therapies to promote neurological repair

Alzheimer’s & tauopathies

LRP1-targeting molecules have the ability to reduce the spread of tau, which is a central pathology in tauopathies like Alzheimer's and CTE. Learn more →

Spinal cord injury (SCI)

Our first-in-class therapeutic has demonstrated significant functional motor recovery in animal models. Learn more →

Multiple sclerosis (MS)

Our approach has shown the ability to increase remyelination, which can reduce disease severity and improve long-term prognosis. Learn more →

Our approach to neuroregeneration & remyelination in the CNS

Our process

At Novoron, we’re exacting in our process. We believe that when you’re attempting to address conditions with unmet needs, you can’t risk shortcuts. We’re singularly focused on making sure that when our drugs go to trial, every variable has been exhaustively considered in order to get effective treatments into the hands of the people who need them.

Our science

Targeting LRP1 mediates a major cause of neuroregenerative failure. Our technology is a breakthrough that restores the body’s natural ability to regenerate tissues of the brain and spinal cord after damage or disease.

Find out more